DelveInsight has launched a new report on “Psoriatic Arthritis – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Psoriatic Arthritis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Psoriatic Arthritis Market Report:
The prevalence of PsA among the in large population-based medical records database in the UK (The Health Improvement Network) was 0.19% (95% CI 0.185%, 0.193%) and among patients with confirmed psoriasis was 8.6% (95% CI 7.7%, 9.5%) (Ogdie et al., 2013)
According to study by Pérez et., al (2020), the prevalence of PsA in Spain was among the highest reported to date, only below that reported in Norway (0.67%) and slightly higher than that reported in Italy (0.42%).
PsA was identified in 431 of 3021 patients with psoriasis, with a mean prevalence of 14.3% (range, 8.8–20.4%) in Japan(Ohara, et., al 2015)
According to a retrospective study of German healthcare insurance data, PsA had prevalence rates of 0.3% respectively, in 2016 (Grellmann et al., 2020).
Key benefits of the report:
Psoriatic Arthritis market report covers a descriptive overview and comprehensive insight of the Psoriatic Arthritis Epidemiology and Psoriatic Arthritis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Psoriatic Arthritis market report provides insights on the current and emerging therapies.
Psoriatic Arthritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Psoriatic Arthritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psoriatic Arthritis market.
Psoriatic Arthritis Overview
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Clinical manifestations vary greatly between patients. It can present with oligoarticular joint involvement that is typically asymmetric or as a polyarticular disease affecting five or more joints, usually with asymmetric distribution similar to that of rheumatoid arthritis.
Psoriatic Arthritis Market
The dynamics of the Psoriatic Arthritis market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as AbbVie, Sun Pharma, Bristol-Myers Squibb, AbbVie, UCB Biopharma, Pfizer, and others during the forecasted period 2018-2030.
Psoriatic Arthritis Pipeline Therapies and Key Companies
Ilumya: Sun Pharma
Deucravacitinib: Bristol-Myers Squibb
Bimekizumab: UCB Biopharma
Psoriatic Arthritis Market Drivers
Development of Animal Models
Research and Development
Integration of multidisciplinary treatment approach
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Psoriatic Arthritis Patient Share (%) Overview at a Glance
5. Psoriatic Arthritis Market Overview at a Glance
6. Psoriatic Arthritis Disease Background and Overview
7. Psoriatic Arthritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Psoriatic Arthritis
9. Psoriatic Arthritis Current Treatment and Medical Practices
10. Unmet Needs
11. Psoriatic Arthritis Emerging Therapies
12. Psoriatic Arthritis Market Outlook
13. Country-Wise Psoriatic Arthritis Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Psoriatic Arthritis Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
“Psoriatic Arthritis Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psoriatic Arthritis market. A detailed picture of the Psoriatic Arthritis pipeline landscape is provided, which includes the disease overview and Psoriatic Arthritis treatment guidelines.
DelveInsight’s ‘Psoriatic Arthritis Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Psoriatic Arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States